MedStar Authors catalog › Details for: Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.
Normal view MARC view ISBD view

Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.

by Krishnan, Jayashree; Jonklaas, Jacqueline; Burman, Kenneth D; Carroll, Nancy M; Felger, Erin A.
Citation: Future Science OA. 4(1):FSO249, 2018 Jan.Journal: Future science OA.Published: 2018ISSN: 2056-5623.Full author list: Jonklaas J; Murthy S; Liu D; Klubo-Gwiezdzinska J; Krishnan J; Burman KD; Boyle L; Carrol N; Felger E; Loh YP.UI/PMID: 29255621.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Washington Hospital CenterDepartment(s): Pathology | Medicine/Endocrinology | Surgery/General Surgery | Surgery/Endocrine SurgeryActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: (Click here) Abbreviated citation: Future Sci OA. 4(1):FSO249, 2018 Jan.Abstract: Aim: To investigate biomarkers for predicting papillary thyroid cancer outcomes.Abstract: Materials & methods: The expression of biomarkers (ITGA2, SYT12 and CDH3) was studied in a prospective cohort of patients with papillary thyroid cancer. Three outcomes of initial metastases, baseline status and longitudinal status were analyzed and correlated with the biomarkers.Abstract: Results: SYT12 provided the best prediction of initial metastasis (sensitivity: 72%; specificity: 54%). SYT12 had the highest accuracy for predicting longitudinal status (sensitivity: 100%; specificity: 47%). The best performance for longitudinal status resulted from combining SYT12 with American Thyroid Association risk stratification, with sensitivity and specificity of 88 and 73%, respectively.Abstract: Conclusion: SYT12 has some prognostic significance in papillary thyroid cancer. Further validation studies in larger populations are warranted.

Powered by Koha